Zinc finger protein GLI1 (GLI1) (GLI1)

Zinc finger protein GLI1 (GLI1) is a member of the Kruppel family of transcription factors and serves as the primary terminal effector of the Hedgehog (Hh) signaling pathway (UniProt P08151, NIH). It plays a critical role in embryonic development, tissue patterning, and the maintenance of adult stem cells by regulating the expression of genes involved in cell cycle progression, survival, and differentiation (Wikipedia, NIH). In many human malignancies, GLI1 is aberrantly activated through both canonical (Hh-ligand dependent) and non-canonical (Hh-independent, e.g., RAS, PI3K/AKT) pathways, promoting tumor growth, metastasis, and therapeutic resistance (PubMed, NIH). Consequently, GLI1 has emerged as a significant therapeutic target, particularly for cancers that develop resistance to upstream Smoothened (SMO) inhibitors (ResearchGate, NIH). Current drug development efforts focus on small molecules that directly inhibit GLI1 by disrupting its DNA-binding activity or promoting its degradation, although most of these agents remain in the preclinical stage (PubMed, NIH). Targeting GLI1 offers a potential strategy to overcome resistance mechanisms that bypass SMO, making it a high-priority node in oncology research (Frontiers in Oncology). However, therapeutic challenges include the potential for off-target effects on normal developmental processes and the poor pharmacological properties of many current direct inhibitors (PubMed).

Other names

GLIGlioma-associated oncogene 1GLI family zinc finger 1PAPA8PPD1

Inhibition of GLI1-mediated transcription by disrupting GLI1-DNA interaction, preventing nuclear translocation, or promoting protein degradation.